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A mobile, typically seen in an infant’s crib, is an eloquent representation of the balance 
between multiple items. The neurochemical mobile is a tool used to visualize the balance 
between six major neurotransmitters in the human brain. Neurotransmitters are chemical 
compounds that govern the behavior of the brain. Here, this somewhat abstract model has been 
converted into a more applicable form. This was done using nonlinear computational systems 
modeling within the framework of biochemical systems theory, which allows even ill-
characterized systems to be mapped into a mathematical representation. The interactions between 
the individual neurotransmitters and the system are described by the “neurochemical interaction 
matrix”. This matrix explicitly records whether the reaction between two neurotransmitters is 
excitatory or inhibitory. These interactions have an effect on the concentrations of the six 
compounds, which in turn make up the symbolic weight. The various weights are then 
incorporated into a model of a spring-mass system in order to quantitatively represent overall 
shifts in balance upon alterations in weights. Simulations show how short- and long-term 
perturbations in any of the neurotransmitters migrate through the entire system, thereby affecting 
the balances within the mobile. In cases of short-term alterations, transients are of particular 
interest, whereas long-term changes shed light on persistently altered, allostatic states, which in 
mental diseases and sleep disorders could be due to a combination of unfavorable factors, 
resulting from a specific genetic predisposition, epigenetic effects, disease, or the repeated use of 
drugs, such as opioids and amphetamines. Based on the research done here, the Voit lab 
continued this line of investigation and published the paper, “The Neurochemical Mobile with 






Neurotransmitters are the basis for many bodily functions and processes. It is these 
chemical compounds that allow for communication between different parts of the brain, as well 
as between the brain and the body. In addition to the very prevalent excitatory and inhibitory 
neurotransmitters glutamate and GABA, there are four other neurotransmitters that have a large 
impact. These are acetylcholine, norepinephrine, dopamine, and serotonin. It is essential to have 
these six chemicals in the correct balance to ensure healthy function. Any significant 
perturbations to this balance tend to cause a number of pathologies. A complicated network 
governs the interactions of these modulators 
[1]
.  
Substance abuse is defined as a syndrome characterized by symptoms such as 
withdrawal, tolerance, persistent desire, unsuccessful attempts to quit, and the use of larger than 
intended amounts of the substance. Many times drug abuse and substance dependence are used 
interchangeably. However, it is important to note that drug abuse refers to any maladaptive 
pattern of drug use resulting in occupational, social, or recreational problems for the user, 
whereas addiction causes neural plastic changes such as withdrawal, tolerance, and sensitization. 
A main factor of drug abuse is the reinforcement or reward provided by the central nervous 
system, which leads to the long lasting effects created by addiction. The rewards are caused by 
the physiological effect that drugs have on the nervous system. Drugs of abuse typically act on 
proteins at specific synapses. This will typically lead to an imbalance in the functional levels of 
neurotransmitters 
[2] [3]
. The purpose of this project is to develop a model capable of quantifying 
these interactions and the consequences of their alterations. The goal is to both provide a useful 
model for a healthy system, while providing the opportunity to investigate problems such as drug 
abuse. In particular, this paper will address the neurological effects of opioids. This will be 
achieved using a systems biology approach.  
Computational biology has exploded over the last two decades due the increasing level of 
information available through molecular biology and vastly expanded computing power. The 
discipline addresses two main goals. The first is to discover new organizing principles that 
govern biological phenomena such as metabolic processes. The second goal is to create effective 
disease simulators that will function in predicative health and personalized medicine. These must 
be simple yet accurate enough to be used in a clinical setting. It is clear that these goals call for a 
move in opposite directions in the size and complexity of desired models. In the last decade, 
most models have not yet been able to accomplish either goal. One partial solution to the 
challenge is a framework known as mesoscopic modeling. This approach allows for the potential 
to achieve both goals when they are expanded further or used as part of a larger model. It has the 
future potential for clinical applications and yet can serve as a template capable of supporting 
small detailed “anchor” models that allow studies of design and function 
[4][5]
. 
 The neurochemical mobile will be designed as such a mesoscopic model with the 
modeling framework of Biochemical Systems Theory (BST) 
[4]
. It represents the functional 
weight of the six neurotransmitters on a dynamic balance or scale. The balance will be governed 
by interactions among the six highlighted molecules. The mobile will have educational, clinical 
and research applications. It will be capable of aiding in the treatment of certain pathologies by 
suggesting a necessary change in the concentrations of neurotransmitters. Furthermore, as any 
good mesoscopic model can do, it will have room for more specific anchor models which will 






 The six neurotransmitters were represented as follows: X1 Norepinephrine, X2 
Acetylcholine, X3 Dopamine, X4 Glutamate, X5 Serotonin, X6 GABA. Initial values were set as: 
X1(0) ~ .0035µM
[7][8]
, X2(0) ~ .003 µM, X3(0) ~ 1.14e-4 µM
[9]
, X4(0) ~ 2 µM
[10][11][12]
, X5(0) ~ 
1.14 µM
[13]
, X6(0) ~ .25 µM
[14][15]
. These initial values of each neurotransmitter were 
subsequently scaled to a relative value. The highest concentration, X4(0), was set at 10,000. The 
remaining concentrations were adjusted proportionately. The value for the kinetic orders and rate 
constants, which are the prominent parameter values in BST, were set based on previous 
experience. The kinetic orders were set at .5 for activation and -.3 for inhibition. The rate 




The model was created under the paradigm of Biochemical Systems Theory (BST) 
[4]
. 
BST uses two main components. The ability to describe biochemical systems using ODE’s and 
the representation of all processes that govern these systems through products of power law 
functions. One class of BST model is an S-system model 
[4]
, which is applied here. It constitutes 
of equations that represent the dynamic change of variables Xi. in particular, the format consists 
of the difference between one influx term and one efflux term, as shown below.  
 
 
Each flux is described as a power-law term. The first term represents synthesis of the variable 
being described and the second represents degradation. Kinetic orders are represented by doubly 
indexed g and h, respectively. A positive kinetic order signifies activation, a negative one 
signifies inhibition 
[16]
. The parameters alpha and beta denote the rate constants of synthesis and 
degradation, respectively. Not only does the power law provide an accurate representation of rate 
laws, many features of S-system models are consistent with features of biochemical systems (see 
[4] for details). 
The neurochemical mobile assigns a functional weight to each neurotransmitter. Each weight 
is in dynamic balance with the rest of the system (Fig. 1). The dynamic interactions between the 
weights can be quantified by the change in overall balance. An equation for each balance was 
generated using the neurochemical mobile schematic. Each region of the brain is interconnected 
through a mesh of axons and synapses. This mesh results in constant interaction between 
neurotransmitters. The activation of one neurotransmitter often leads to the activation or 
inhibition of another. Therefore, the ability to quantify the balance between concentrations of 
neurotransmitter could prove to be very valuable.  
A system of ODE’s was created that describes the change in each neurotransmitter with an S-
system model. Using the neurochemical interaction matrix (Fig. 2), activation and inhibition 
effects were included into the degradation term in the form of power-law terms. Simulations 
were then run in Power Law Analysis Software (PLAS), in order to test the robustness of the 
system and search for critical parameter values. For a preliminary diagnosis, the initial values 
were both increased and decreased 10 fold. A local sensitivity analysis was performed on the 
kinetic orders, as well as a global sensitivity analysis. These simulations shed light on which 
variables are the most critical. The ones that have larger effects on the system when changed are 
said to be the most critical. Sensitivity analysis was also performed for kinetic orders with initial 
values of .3 for activation and -.1 for inhibition. The global sensitivities of kinetic orders 3_5 and 
4_6 turned out to be high, and these kinetic orders were therefore tested over the range of values 
.3 to -1 and .45 to .75, respectively. A dynamic perturbation or permanent change was evaluated 
at  t=5000 seconds. This was done by increasing and decreasing the neurotransmitter 
concentration by 50% and setting the variable representing dynamic change for that 
neurotransmitter to zero at the indicated time. The eigenvalues were assessed to assure stability 
of the steady state. Finally, opiate was introduced, and its effect on each neurotransmitter  









                             





We assessed the global stability of the system by increasing and decreasing the 
initial values individually by a factor of 10. The results confirmed a robust steady state. 
For all temporary changes, that is, changes to the initial values, the system returned 
quickly to its original steady state. The global sensitivities were also assessed by 
changing the kinetic orders by 25%. The system harbors several large sensitivities. These 
could indicate the more critical parameters. ACh proved to have the largest effects. To 
analyze the situation further, we permanently changed the concentration of individual 
neurotransmitters and assessed the effect on the system. In each simulation where a 
structural change was applied, the system never became unstable. Rather, a monotonic 
shift from the original steady state was observed. The value that caused the largest shift in 
the system was X2 (acetylcholine). The added opiate concentration caused a similar 
monotonic shift. The largest effect due to the opioid was observed on X1 






% X1 20927.65 Up 
% X2 38.78 Down 
% X3 21158.56 Up 
% X4 1752.34 Up 
% X5 605.93 Up 
% X6 1.03 Down 
 
It should be noted that the work done here was continued by the Voit laboratory, 
leading to a peer-reviewed publication
 [19]
. Also, a poster was presented based on this 
continued work at the international conference Frontiers in Systems and Synthetic 




The goal of the neurochemical mobile is three fold: academic, educational and 
clinical. The results address all three goals. The fact that the model showed a robust 
steady state is in line with most natural systems. The human brain is quite resistant to 
most changes in neurotransmitter concentrations. It is difficult to cause the system to 
become unstable. Further research allows additive diagnostic evaluations. The possibility 
to create a detailed system model of the interactions of neurotransmitters could lead to the 
discovery of underlying design and operating principles.  Finally, each structural 
perturbation, as well the addition of opiates showed a different monotonic shift in steady 
state. This set of results can be very useful in clinical applications because it allows for 
the prediction of neurotransmitter levels based on certain perturbations that could be due 
to disease or substance abuse. The monotonic shift could be countered by making the 
correct changes in either neurotransmitter concentrations or the re-uptake of certain 
neurotransmitters. This possibility suggests a future direction for the project that would 
make it useful for training physicians and the public. A direct, quantitative connection 
 2 
between the resulting values of the neurotransmitters after a shift and the altered balance 
of the mobile has been made by Mojdeh Faraji. She utilized a functional weight and 
modeled each beam as a cantilever free body system. For example, healthy levels of 
neurotransmitters will show a certain balance. By quantifying changes to this balance, 
Faraji’s model will make it possible to go from a shift in the mobile to the correct change 
in neurotransmitter level. This would open new possibilities when prescribing drugs for 
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